OpenBit ResearchOpenBit
中文

What's driving Gilead Sciences (GILD)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Gilead Trodelvy-Keytruda First-Line TNBC Expansion

Why it matters now

The European authorization adds a first-line combination treatment setting for Trodelvy in a defined metastatic triple-negative breast-cancer population, creating a potential revenue expansion channel.

Next checkpoint

GILD earnings (expected 2026-10-29)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to GILD, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Eligible-patient adoption remains limited or the expanded indication fails to produce durable Trodelvy demand or oncology revenue.

Research drivers

  • Gilead Trodelvy-Keytruda First-Line TNBC Expansion

    Bullish · Active · Updated

    The European authorization creates a biomarker-selected first-line opportunity for Trodelvy in metastatic triple-negative breast cancer, with commercial scale dependent on eligible-patient adoption.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • The European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for adults with unresectable, locally advanced or metastatic triple-negative breast cancer who have not received prior systemic

    Source: Business Wire · Event date on record:

  • Gilead's August 4, 2026 update projected a 2026 GAAP diluted loss per share of $(3.75) to $(3.40) and non-GAAP diluted loss per share of $(0.65) to $(0.30).

    Source: EDGAR · Event date on record:

  • Gilead states that it may be unable to receive or maintain regulatory approvals in a timely manner or at all, including for Hepcludex, Trodelvy and once-weekly oral Yeztugo.

    Source: EDGAR · Event date on record:

  • Gilead states that its ability to achieve its full-year 2026 financial guidance is subject to risks and uncertainties, including uncertainty regarding the amount and timing of Veklury revenues and the impact of Medicare Part D pri

    Source: EDGAR · Event date on record:

  • Gilead received FDA approval of Trodelvy for first-line treatment of certain adults with unresectable locally advanced or metastatic triple-negative breast cancer.

    Source: EDGAR · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.